These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19632367)

  • 21. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
    Halliday GM; Macdonald V; Henderson JM
    Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inside SMP proteomics: six years German Human Brain Proteome Project (HBPP) - a summary.
    Hamacher M; Hardt T; van Hall A; Stephan C; Marcus K; Meyer HE
    Proteomics; 2008 Mar; 8(6):1118-28. PubMed ID: 18283670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Update on the pathophysiology of Parkinson' disease].
    Duyckaerts C; Sazdovitch V; Seilhean D
    Bull Acad Natl Med; 2010 Oct; 194(7):1287-303; discussion 1303-4. PubMed ID: 22043625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease.
    Mochizuki A; Komatsuzaki Y; Shoji S
    Acta Neuropathol; 2002 Nov; 104(5):534-7. PubMed ID: 12410401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis of Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's and Parkinson's diseases: an environmental proteomic point of view.
    Demartini DR; Schilling LP; da Costa JC; Carlini CR
    J Proteomics; 2014 Jun; 104():24-36. PubMed ID: 24751585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.
    Singh MP; Patel S; Dikshit M; Gupta YK
    Indian J Biochem Biophys; 2006 Apr; 43(2):69-81. PubMed ID: 16955754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the Pathogenesis Involved in Parkinson's Disease and Potential Therapeutic Treatment Strategies.
    Dhanawat M; Mehta DK; Gupta S; Das R
    Cent Nerv Syst Agents Med Chem; 2020; 20(2):88-102. PubMed ID: 32628600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.
    Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR
    Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of alpha-synuclein in Parkinson's disease].
    Miklya I; Pencz N; Hafenscher F; Göltl P
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report.
    Wu CK
    Acta Neurol Taiwan; 2011 Mar; 20(1):4-14. PubMed ID: 21560084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.
    Meredith GE; Halliday GM; Totterdell S
    Parkinsonism Relat Disord; 2004 Jun; 10(4):191-202. PubMed ID: 15120093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pathomechanisms underlying Parkinson's disease.
    Jellinger KA
    Expert Rev Neurother; 2014 Feb; 14(2):199-215. PubMed ID: 24471711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
    Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.